Kumar Srinivasan
Directeur/Membre du Conseil chez TRANSCENTA HOLDING LIMITED
Fortune : 6 943 $ au 30/04/2024
Profil
Kumar Srinivasan is currently the President & Chief Executive Officer at Wugen, Inc. He is also a Director at Pulmotect, Inc. and an Independent Non-Executive Director at Transcenta Holding Ltd.
Previously, he worked as the Chief Business Officer & Executive Vice President at Turning Point Therapeutics, Inc. Dr. Srinivasan holds a doctorate degree from Case Western Reserve University, undergraduate and graduate degrees from the University of Madras, and an MBA from The University of Chicago Booth School of Business.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
06/04/2023 | 30 000 ( 0,01% ) | 6 943 $ | 30/04/2024 |
Postes actifs de Kumar Srinivasan
Sociétés | Poste | Début |
---|---|---|
TRANSCENTA HOLDING LIMITED | Directeur/Membre du Conseil | 19/12/2022 |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | - |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Directeur Général | 13/03/2023 |
Anciens postes connus de Kumar Srinivasan
Sociétés | Poste | Fin |
---|---|---|
TURG POIN | Corporate Officer/Principal | - |
Formation de Kumar Srinivasan
Case Western Reserve University | Doctorate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
University of Madras | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
TRANSCENTA HOLDING LIMITED | Health Technology |
Entreprise privées | 3 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Pulmotect, Inc.
Pulmotect, Inc. BiotechnologyHealth Technology Pulmotect, Inc. develops clinical stage, novel, pathogen-agnostic, inhaled compound for the prevention and early treatment of acute, severe viral and bacterial respiratory infections. It provides safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded by Brenton Scott and Magnus Hook in 2007 and is headquartered in Houston, TX. | Health Technology |
Wugen, Inc.
Wugen, Inc. Packaged SoftwareTechnology Services Wugen, Inc. develops CAR-T therapy platform for cancer therapies. The company was founded by Matthew Cooper and John F. DiPersio and is headquartered in St. Louis, MO. | Technology Services |